B

BeiGene Ltd
D

BGNE

190.530
USD
-4.05
(-2.08%)
Market Closed
Volume
9,448
EPS
-6
Div Yield
-
P/E
-23
Market Cap
20,313,932,303
OverviewSignalsIdeasNews
Related Instruments
    ALNY
    ALNY
    -22.650
    (-8.77%)
    235.480 USD
    A
    ARCT
    -2.310
    (-12.60%)
    16.020 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    T
    TBIO
    0
    (0%)
    0.000000 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    More
News

Title: BeiGene Ltd

Sector: Healthcare
Industry: Biotechnology
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies witha contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.